151. Lung cancer in transplant recipients: a single-institution experience.
- Author
-
Ahmed Z, Marshall MB, Kucharczuk JC, Kaiser LR, and Shrager JB
- Subjects
- Adult, Aged, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Prevalence, Smoking epidemiology, Survival Analysis, Lung Neoplasms epidemiology, Organ Transplantation adverse effects, Risk Factors
- Abstract
Hypothesis: That aggressive surgical treatment of lung cancer (LC) is justified by stage-based outcome in immunosuppressed solid organ transplant recipients., Design: Case series., Setting: University hospital., Patients: Lung cancer developed in 15 patients (0.28%) among a solid organ transplant recipient population of 5400 accrued at our institution over a 25-year period., Main Outcome Measures: Smoking prevalence, subtypes and stages of LC represented, operative morbidity, and survival., Results: The mean time from transplantation to the diagnosis of LC was 76 months (range, 9-192 months). Eight patients received kidneys; 3, lungs; and 4, hearts. Only 11 patients (73%) had a smoking history (mean, 66 pack-years). The following carcinomas developed in our patient population: adenocarcinoma, 6 patients; squamous cell, 5; large cell undifferentiated, 2; bronchoalveolar, 1; and small cell, 1. Eight patients (53%) presented with inoperable stage IIIB or IV disease. The remaining patients presented in stages IA (n = 2), IB (n = 1), IIB (n = 2), and IIIA (n = 2); all underwent resection. No major postoperative complications occurred. All patients with stage IIIB or greater disease with or without treatment died quickly (mean survival, 1.4 months; range, 0.33-3.0 months). All patients with stage IIB or less remain alive a mean of 37 months after resection. Patients with stage IIIA survived only a mean of 6.0 months despite resection., Conclusions: Regarding LCs in transplant recipients compared with LCs in the nontransplant population, we find that (1) there is an increased incidence among nonsmokers; (2) death occurs rapidly in unresected patients; (3) resection carries a low morbidity rate; and (4) resection seems to offer a high chance of cure in those with cancers staged IIB or less.
- Published
- 2004
- Full Text
- View/download PDF